Paris Panayiotopoulos is a Senior Managing Director in the Blackstone Life Sciences group, having joined Blackstone as part of its acquisition of Clarus in December of 2018.
In over twenty years in the biopharmaceutical industry, Mr. Panayiotopoulos also served as Operating Partner at Clarus, as CEO and President of Ariad Pharmaceuticals (NASDAQ: ARIA, sold to Takeda in 2017), as member of the Board of Directors of The Medicines Company (NASDAQ: MDCO, sold to Novartis in 2020), as President of the US and Japan biopharmaceutical businesses of Merck KGaA (FWB: MRK), as President of the Serono Research and Development Institute, and as Board Director of Corbus Pharmaceuticals (NASDAQ: CRBP). Mr. Panayiotopoulos is currently founding Co-Chair of FerGene, founding Board Director of Anthos Therapeutics and on the Board of Advisors of the non-profit Life Science Cares.
Prior to joining Merck KGaA, Mr. Panayiotopoulos was at Eli Lilly & Co. (NYSE: LLY). He holds a combined BS in Chemistry and Management Studies from University College London and a MS from Cranfield Business School in the United Kingdom.